News Search Results
Jan 12, 2026, 09:30 ET Trailhead Biosystems Expands Financing to $40 Million
www.trailbio.com), a biotechnology company advancing human cell innovation, has added $20 million in new funding, expanding the financing announced in May 2025 to $40 million. The
More news about: Trailhead Biosystems Inc
Jan 12, 2026, 09:00 ET Debut Appoints Derek Wanner as Chief Commercial Officer Amid Rapid Growth of Its Formulation Business
diverse portfolio of global beauty brands – experience he now brings to Debut, leveraging biotechnology as a competitive advantage."What drew me to Debut is its ability to pair world-class biotechnology with a clear path to commercialization. Debut's science-first approach represents a fundamental
More news about: Debut Biotechnology
Jan 12, 2026, 08:42 ET Fresh Inset Appoints Gordon Robertson as General Manager, North America
privately held produce companies and venture-backed biotechnology startups. These include more than two decades at Campbell Soup Company, followed by leadership roles in agriculture marketing and operations at Sun World International, biotechnology leadership positions with Apeel and Verdant Technologies,
More news about: Fresh Inset S.A.
Jan 12, 2026, 08:30 ET Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
published in Nature Biotechnology, underlining the innovation and translational potential of Insilico's AI-driven drug discovery platform.Notably, Insilico Medicine recently licensed out ISM4808, a novel drug candidate also under the PHD program, to TaiGen Biotechnology for the treatment
More news about: Insilico Medicine
Jan 12, 2026, 08:30 ET Operationalizing ADC Clinical Trials: Best Practices for Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 12, 2026, 08:30 ET Using Recombinant Insulin and Trypsin for Safer Vaccine Production, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 12, 2026, 08:05 ET Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe's interest in entering a global exclusive licensing
More news about: OSR Holdings
Jan 12, 2026, 08:05 ET Rigel Provides Business Update and 2026 Outlook
Calif., Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales
More news about: Rigel Pharmaceuticals, Inc.
Jan 12, 2026, 08:00 ET Invictus Therapeutics and Breakthrough T1D Announce Collaboration to Support First-in-Human Trial of Next-Generation Insulin Analog
WARWICK, R.I., Jan. 12, 2026 /PRNewswire/ -- Invictus Therapeutics, a biotechnology company developing next-generation insulin analogs engineered for automated insulin delivery systems, today announced it has received an Industry
More news about: Invictus Therapeutics, LLC
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced an expanded manufacturing partnership
More news about: Minaris Advanced Therapies
Jan 12, 2026, 07:03 ET SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
Improvements Act of 1976 and other customary conditions.About SciNeuro Pharmaceuticals SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio
More news about: SciNeuro Pharmaceuticals
Jan 12, 2026, 07:00 ET NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
-- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced
More news about: NewcelX Ltd.
Jan 12, 2026, 07:00 ET Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise
12, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors ("McKinney"), a premier FDA regulatory
More news about: Doseology Sciences Inc.
Jan 12, 2026, 07:00 ET EDETEK to Present at the 44th Annual J.P. Morgan Healthcare Conference
www.edetek.com.About EDETEKFounded in 2009, EDETEK provides AI-powered platforms and clinical services to pharmaceutical, biotechnology and medical device companies worldwide. The company serves more than one hundred and twenty biopharma clients across four continents with a focus
More news about: EDETEK, Inc.
Jan 12, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Samil Pharmaceuticals.About Formosa Pharmaceuticals, Inc.Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
Jan 11, 2026, 23:52 ET Architects of Progress: Celebrating India's Most Influential Knowledge Leaders
emerging as one of India's most dynamic biotechnology and green innovation enterprises, redefining the intersection of science, sustainability, and entrepreneurship. Formerly known as JE JE Enterprises Private Limited, the organisation operates across algae biotechnology, nutraceuticals, controlled-environment
More news about: Kiteskraft Productions LLP
Jan 11, 2026, 23:33 ET Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment
More news about: Clover Biopharma
Jan 11, 2026, 19:00 ET Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 11, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief
More news about: Argo Biopharmaceutical Co., Ltd
Jan 11, 2026, 15:00 ET REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
of the webcast will be available for approximately 30 days following the presentation.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jan 09, 2026, 13:27 ET Ventaris Surgical, Inc. Announces $30M Series A to Advance a Next-Generation System for Complete Kidney Stone Treatment
http://www.ventarissurgical.comAbout Longitude CapitalLongitude Capital is a private investment firm that makes venture growth investments in biotechnology and technology-enabled healthcare companies. The firm has raised over $2.4 billion in capital to-date to help achieve regulatory approvals, scale
More news about: Ventaris Surgical, Inc.
Jan 09, 2026, 10:30 ET Human Microbiome Drugs Market worth $2.13 billion by 2031 | MarketsandMarkets™
others.Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial (
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jan 09, 2026, 08:02 ET iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
Morgan Healthcare Conference is an invite-only event that serves as a vital forum for innovation and capital formation across the pharmaceutical and biotechnology sectors. Participation reflects iOnctura's growing visibility within the global oncology ecosystem and underscores the company's progress towards
More news about: iOnctura
Jan 09, 2026, 08:00 ET Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced that Tom Barnes, Ph.D., Chief Executive Officer,
More news about: Averna Therapeutics